Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
0.5462
+0.0240 (4.60%)
At close: Jan 16, 2026, 4:00 PM EST
0.5300
-0.0162 (-2.97%)
After-hours: Jan 16, 2026, 7:54 PM EST
Outlook Therapeutics Employees
Outlook Therapeutics had 17 employees as of September 30, 2025. The number of employees decreased by 6 or -26.09% compared to the previous year.
Employees
17
Change (1Y)
-6
Growth (1Y)
-26.09%
Revenue / Employee
$83,149
Profits / Employee
-$3,672,051
Market Cap
35.02M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 17 | -6 | -26.09% |
| Sep 30, 2024 | 23 | -1 | -4.17% |
| Sep 30, 2023 | 24 | 7 | 41.18% |
| Sep 30, 2022 | 17 | 8 | 88.89% |
| Sep 30, 2021 | 9 | 1 | 12.50% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
OTLK News
- 13 days ago - Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development - GlobeNewsWire
- 19 days ago - US FDA declines to approve Outlook Therapeutics' eye disease drug - Reuters
- 19 days ago - Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD - GlobeNewsWire
- 22 days ago - Third Time's The Charm: Outlook Therapeutics Lytenava Heads To FDA, Again - Seeking Alpha
- 24 days ago - Outlook Therapeutics Announces New Employment Inducement Grants - GlobeNewsWire
- 4 weeks ago - Outlook Therapeutics Reports Financial Results for Fiscal Year 2025 - GlobeNewsWire
- 2 months ago - Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 2 months ago - Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD - GlobeNewsWire